---
title: "Transtek's blood glucose monitoring products have passed the medical device registration approval by the U.S. FDA"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/227173959.md"
description: "According to the Zhitong Finance APP, Transtek announced that the company recently received a notification from the U.S. FDA, informing that the medical device registration for the blood glucose monitoring product applied by the company has been approved"
datetime: "2025-02-05T07:59:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/227173959.md)
  - [en](https://longbridge.com/en/news/227173959.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/227173959.md)
generator: "portal-rs"
---

# Transtek's blood glucose monitoring products have passed the medical device registration approval by the U.S. FDA

According to the Zhitong Finance APP, Transtek (300562.SZ) announced that the company recently received a notification from the U.S. FDA, informing that the medical device registration application for its blood glucose monitoring product has been approved

### Related Stocks

- [300562.CN](https://longbridge.com/en/quote/300562.CN.md)
- [600521.CN](https://longbridge.com/en/quote/600521.CN.md)
- [301234.CN](https://longbridge.com/en/quote/301234.CN.md)
- [688553.CN](https://longbridge.com/en/quote/688553.CN.md)
- [300942.CN](https://longbridge.com/en/quote/300942.CN.md)

## Related News & Research

- [Cofoe Medical FY26 H1 profit climbs 21.9% to RMB 203.2 million; revenue rises 38.5% to RMB 2.07 billion](https://longbridge.com/en/news/297291709.md)
- [Frontieras North America Highlights Aug. 27 Reg A+ Offering Deadline, Advances West Virginia FASForm Facility](https://longbridge.com/en/news/297213635.md)
- [FDA approves PharmaEssentia BESREMi for adults with essential thrombocythemia](https://longbridge.com/en/news/297513690.md)
- [Oryzon Genomics wins US notice of allowance for iadademstat-gilteritinib AML patent application](https://longbridge.com/en/news/297475261.md)
- [IBA publishes H1 2026 results presentation](https://longbridge.com/en/news/297180350.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**